Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in...
Day: May 9, 2023
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high...
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of...
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May...
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extensionYAVNE, Israel, May 09, 2023 (GLOBE...
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.),...
Cronos Group Reports 2023 First Quarter Results
Industry-leading balance sheet with $836 million in cash and short-term investments Targeting positive cash flow in 2024 Net revenue in...
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX®2-73-AD-004 study; allowing initiation of discussions with regulatory agencies for...
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology...
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose...
Vivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations
Moss Adams LLP also appointed as new independent registered public accounting firmLITTLETON, Colo., May 09, 2023 (GLOBE NEWSWIRE) -- Vivos...